Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.58 |
| ▸ | PNP | P00491 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716514 | 0.82 | FGFR1 (0.48) | FGFR1FGFR2PNPKDM4EMEN1 | |
| SCHEMBL14716708 | 0.82 | PNP (0.47) | FGFR1FGFR2PNP | |
| SCHEMBL12320442 | 0.77 | ALDH1A1 (0.53) | PNPALDH1A1CYP1A2HIF1AKDM4E | |
| SCHEMBL14716576 | 0.77 | ALDH1A1 (0.53) | PNPALDH1A1CYP1A2HIF1AKDM4E | |
| SCHEMBL1301998 | 0.76 | PNP (0.68) | FGFR1FGFR2PNPALDH1A1KDM4E | |
| SCHEMBL1286943 | 0.74 | FGFR1 (1.00) | FGFR1FGFR2PNPALDH1A1MEN1 | |
| SCHEMBL14716553 | 0.73 | PNP (0.44) | FGFR1FGFR2PNPALDH1A1KDM4E | |
| 8-Aminoguanine SCHEMBL21761 | 0.73 | PNP (1.00) | FGFR1FGFR2PNPALDH1A1HIF1A | |
| SCHEMBL11498906 | 0.72 | FGFR1 (0.47) | FGFR1FGFR2PNPALDH1A1MEN1 | |
| SCHEMBL10339631 | 0.72 | PNP (0.61) | FGFR1FGFR2PNPALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108273478-B | Formaldehyde removal composition and product | 李怀玉 | 2021-03-02 | — | — | CN | disclosed |
| CN-108273478-A | A kind of formaldehyde removing composition and product | 李怀玉 | 2018-07-13 | — | — | CN | disclosed |
| US-9458515-B2 | RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound | RIKEN (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RIKEN (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RNMT, NSUN2, RNGTT | FGFR1 4325/4885FGFR2 4803/4885PNP 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.